The Independent Voice of
European Private Equity

Advanced Search

Biopharma M&A activity hits $190bn but set to slow

Samantha Birchall 9 August 2019

There has been a surge of M&A activity across the Biopharma space in the past twelve months. However, healthcare-focused buyout firm HBM Partners said deal flow is expected to slow in the coming months, at least for a period of...

Related Articles

ThinCats launches regional fund

26/03/24

Montagu carves out Johnson Matthey’s MDC

20/03/24

Endless exits Findel investment to Manutan

20/03/24

Kester Capital III closes on £200m hard-cap

20/03/24

Gilde Healthcare sells RAD-x stake to infra consortium

18/03/24

Pricoa picks up minority stake in TeacherActive

18/03/24